Terminated PHASE2 INTERVENTIONAL NCT00127595

Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

A Phase II Monocentric Study of Oxaliplatin in Combination With Gemcitabine in Patients With Advanced/Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Conditions Carcinoma, Transitional Cell

Interventions gemcitabine, oxaliplatin

Updated 5 times since 2017 Last updated: Aug 23, 2005 Started: Jan 31, 2002 Completion: Apr 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Gustave Roussy, Cancer Campus, Grand Paris

See all terminations from Gustave Roussy, Cancer Campus, Grand Paris

Other Carcinoma, Transitional Cell trials with similar outcome

Browse all Carcinoma, Transitional Cell trials

Listed as NCT00127595, this PHASE2 trial focuses on Carcinoma, Transitional Cell and remains terminated or withdrawn. Sponsored by Gustave Roussy, Cancer Campus, Grand Paris, it has been updated 5 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gustave Roussy, Cancer Campus, Grand Paris

Data source: Gustave Roussy, Cancer Campus, Grand Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Villejuif, France